阿昔洛韦联合转移因子口服液治疗传染性单核细胞增多症患儿的临床效果  

Clinical effect of Acyclovir combined with Transfer Factor Oral Liquid in the treatment of children with infectious mononucleosis

作　　者：孙鹏玲 傅彬 孙瑶 SUN Pengling;FU Bin;SUN Yao(Department of Paediatrics,Nanjing Lishui District People’s Hospital,Jiangsu Province,Nanjing 211200,China)

机构地区：[1]南京市溧水区人民医院儿科,江苏南京211200

出　　处：《中国医药导报》2023年第21期113-116,共4页China Medical Herald

基　　金：江苏省杰出青年学者自然科学基金资助项目(1808085J28)。

摘　　要：目的探究阿昔洛韦联合转移因子口服液治疗传染性单核细胞增多症(IM)患儿的临床效果。方法选取南京市溧水区人民医院2017年1月至2022年4月收治的84例IM患儿作为研究对象,采用随机数字表法将其分为对照组和研究组,各42例。对照组给予阿昔洛韦静脉注射治疗,研究组给予阿昔洛韦联合转移因子口服液治疗。治疗1周后,比较两组临床疗效、咽峡炎消退时间、颈部淋巴结肿大消退时间、退热时间、CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、血清免疫球蛋白G(IgG)、IgA、IgM水平及治疗期间不良反应发生率。结果研究组临床疗效优于对照组(P<0.05)。研究组咽峡炎消退、颈部淋巴结肿大消退及退热时间均短于对照组(P<0.05)。两组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、IgG、IgA、IgM水平均高于治疗前,且研究组高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿昔洛韦联合转移因子口服液应用于传染性IM患儿,更有助于改善免疫功能,提升临床疗效且安全性良好。Objective To explore the clinical effect of Acyclovir combined with Transfer Factor Oral Solution in the treatment of children with infectious mononucleosis(IM).Methods A total of 84 children with IM admitted to Nanjing Lishui District People’s Hospital from January 2017 to April 2022 were selected as the study subjects.They were divided into the control group and study group according to the randem number table method,with 42 cases in each group.The control group were treated with Acyclovir intravenously,and the study group was treated with Acyclovir combined with Transfer Factor Oral Liquid.One week after treatment,the clinical effective rate,the regression time of angina pectoris,the regression time of cervical lymphadenopathy,the regression time of fever,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+),serum immunoglobulin G(IgG),IgA,IgM and the incidence of adverse reactions during treatment were compared between the two groups.Results The curative effect of the study group was higher than that of the control group(P<0.05).The regression time of angina pectoris,the regression time of cervical lymphadenopathy and fever in the study group were shorter than those in the control group(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+),IgG,IgA and IgM were higher than those before treatment,the study group was higher than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Acyclovir Transfer Factor Oral Liquid combined with in the treatment of children with infectious mononucleosis is more helpful to improve immune function,enhance clinical efficacy and good safety.

关 键 词：传染性单核细胞增多症 阿昔洛韦 转移因子 免疫功能 

分 类 号：R725[医药卫生—儿科]